Paul Howe, chief commercial officer at Protega, discusses efforts to combine high tech solutions with pain-management medications.
Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with Jelmyto.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback